Climate change puts Lyme disease in focus for France’s Valneva after COVID blow
LONDON, Aug 8 (Reuters) – With climate change spurring more cases of tick-borne Lyme disease, drugmaker Valneva (VLS.PA) is betting big on a vaccine as it looks beyond disappointing sales of its COVID shot. Although Valneva secured European Union and British regulatory approval, both walked away from contracts worth more than a billion dollars combined, …
Climate change puts Lyme disease in focus for France’s Valneva after COVID blow Read More »